InterCure Ltd
TASE:INCR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
444
1 254
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
InterCure Ltd
Free Cash Flow
InterCure Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
InterCure Ltd
TASE:INCR
|
Free Cash Flow
-₪56.3m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-104%
|
CAGR 10-Years
-31%
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Free Cash Flow
$679m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
52%
|
CAGR 10-Years
-14%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Free Cash Flow
-$17m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Free Cash Flow
-$22.3m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Free Cash Flow
-₪4.3m
|
CAGR 3-Years
32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Free Cash Flow
₪12m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
InterCure Ltd
Glance View
InterCure Ltd. engages in the business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
See Also
What is InterCure Ltd's Free Cash Flow?
Free Cash Flow
-56.3m
ILS
Based on the financial report for Dec 31, 2023, InterCure Ltd's Free Cash Flow amounts to -56.3m ILS.
What is InterCure Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-31%
The average annual Free Cash Flow growth rates for InterCure Ltd have been -63% over the past three years , -104% over the past five years , and -31% over the past ten years .
You don't have any saved screeners yet
